Therefore, we examined whether three major drug candidates for NAFLD/NASH alleviated fat accumulation and reductions in viability and albumin production in HepG2 steatosis OOCs. The gene discussed is ALB; the disease is metabolic dysfunction-associated steatohepatitis.